

Index

A

Anticommons, 123–134

B

Bioethics, 164, 165, 174

Biosafety, 1, 2, 3, 20, 69, 75, 82, 83, 85–96,
103, 104, 105, 108, 112, 113, 116, 160,
161, 163, 171, 178–179, 183

Biosecurity assessment, 107, 110

Biosecurity awareness, 105–111, 116, 117, 180

Biosecurity threat, 110, 112

C

Civil society, 1, 4, 19, 83, 111, 137, 155–175,
183

Computational design, 2, 25, 28, 34, 49–61

Creation of living organisms, 66, 73, 94

D

Designing life, 67, 97

De-skilling and amateur biology, 179

DNA circuits, 2, 26–29

E

Enabling innovation, 3, 95, 122, 124, 127, 135,
143–144, 152, 183

Ethics of Synthetic Biology, 2, 65–78

Experimental evolution, 6, 12, 13, 15, 30

G

Genetic engineering, 2, 13, 15, 16, 17, 19, 49,
67, 68, 72, 73, 74, 87, 102, 150, 158, 159,
163, 165, 167, 168, 172, 173, 175, 178,
181, 183, 156, 157

Genetic engineering, 2, 13–15, 16, 17, 19, 49,
67, 72, 73, 87, 96, 150, 155, 156, 157, 158,
161, 163, 165, 167, 168, 172, 173, 175,
178, 181, 183

Genome minimization, 2, 26, 33–34

GM crops, 3, 141, 148, 150, 151, 152

Governance, 3, 4, 19, 20, 102–117, 144, 145,
148–151, 158, 162, 165, 170, 171, 180, 183

Governance of synthetic biology, 113, 117,
145, 148, 151, 183

H

History of biology, 5, 6, 14

History of synthetic biology, 1, 8, 10

I

Intellectual commons, 3, 121–139

Intellectual property, 1, 17, 20, 38, 70, 75, 123,
124, 125, 127, 128, 129, 134, 137, 138,
146, 148, 160, 163, 166, 171, 182

Introduction to synthetic biology, 2, 23–39,
158

M

Model-based design of biological networks, 50

N

Nanotechnology, 2, 3, 71, 148–149, 156, 158,
161, 162, 166

O

Optimal regulatory systems, 144

Ownership and sharing in synthetic biology, 3,
134

P

Private ownership, 3, 123, 124, 127, 134, 136

Protocell, 2, 25, 26, 32–33, 67, 81, 84, 85,
89–90, 97, 178

5P-strategy, 3, 114, 117

Public debate, 155–175

Public pressure, 151

R

Regulation, 3, 19, 34, 35, 53, 56, 58, 69, 70, 71, 106, 111, 113, 114, 115, 116, 133, 143–144, 149, 152, 158, 161, 162, 163, 169, 171, 183
Risk assessment, 2, 81, 83, 85, 86–91, 159, 178, 179
Role of scientists in ethical discussions, 67, 73

S

Safety engineering, 2, 86, 91–96
SBML models, 51, 56, 58

Societal issues, 4, 108, 155, 162, 180, 183
Synthetic metabolic pathway, 2, 26, 29–31
Synthetic microbial consortia, 2, 26, 36–37

T

Targeted behaviour, 56

U

Unnatural components, 26, 34–36
Unsupervised algorithms, 51, 56, 58